Ashley Shoemaker is an Endocrinology/Metabolic physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 The Vanderbilt Clinic
Nashville, TN 372320001
Telephone
615-322-3000Provider last certified this registry record 24 Mar 2022.
Clinical trials
- Atomoxetine in Melanocortin Obesity Syndrome
Sponsor: Icahn School of Medicine at Mount Sinai
- Glucose Homeostasis in Pseudohypoparathyroidism
Sponsor: Vanderbilt University Medical Center
- Vanderbilt Childhood Obesity Registry
Sponsor: Vanderbilt University Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Soleno Therapeutics, Inc.Program year20251 payment$20,000openpaymentsdata.cms.gov ↗
- Rhythm Pharmaceuticals, Inc.Program year20254 payments$10,311openpaymentsdata.cms.gov ↗
- Chiesi USA, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
3 NIH research awards on record, funded 2014–2025 per NIH RePORTER. The latest:
- Phase 2 Study of Theophylline for the Treatment of Psuedohypoparathyroidism
Vanderbilt University Medical Center
FY2025$363,169R01DK118407 - Phase 2 Study of Theophylline for the Treatment of Psuedohypoparathyroidism
Vanderbilt University Medical Center
FY2024$845,394R01DK118407 - Phase 2 Study of Theophylline for the Treatment of Psuedohypoparathyroidism
Vanderbilt University Medical Center
FY2023$670,316R01DK118407
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”